PD-L1/CD274 mychis fusion protein
ED50
Species
human
Purity
>90 %, SDS-PAGE
GeneID
29126
Accession
验证数据展示
Technical Specifications
| Purity | >90 %, SDS-PAGE |
| Endotoxin Level | <1.0 EU/μg protein, LAL method |
| Biological Activity | |
| Source | |
| Predicted Molecular Mass | |
| SDS-PAGE | |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Programmed cell death ligand 1 (PD-L1, also known as CD274 or B7-H1) is a 290 aa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed by some hematopoietic cell types including macrophages, some activated T cells and B cells, DCs, and is further upregulated upon activation. It is also expressed on many nonhematopoietic cell types. PD-L1 is frequently upregulated in a wide variety of tumors, including melanoma, ovarian, lung, glioblastoma, breast, and pancreatic cancers. PD-L1 and PD-L2 are two ligands of PD-1. Engagement of PD-1 by PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function. It is critical for the regulation of T-cell function during tolerance, autoimmunity and infection. Blockade of the PD-1/PD-L1 pathway has been developed for cancer immunotherapy.
References:
1. Arlene H Sharpe, et al. (2007) Nat Immunol. 8(3):239-45. 2. Mary E Keir, et al. ( 2008) Annu Rev Immunol. 26:677-704. 3. James L Riley. (2009) Immunol Rev. 229(1):114-25. 4. Loise M Francisco, et al. ( 2010) Immunol Rev. 236:219-42. 5. Yanyan Han, et al. (2020) Am J Cancer Res. 10(3):727-742.